Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.64 |
| ▸ | POLA1 | P09884 | 6/20 | 0.52 |
| ▸ | SOD1 | P00441 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29493569 | 0.87 | SOD1 (0.60) | NR1H2NR1H3POLA1SOD1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL28618126 | 0.87 | SOD1 (0.60) | NR1H2NR1H3POLA1SOD1CYP3A4 | |
| SCHEMBL24591823 | 0.85 | SOD1 (0.69) | NR1H2NR1H3POLA1SOD1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL21552217 | 0.84 | POLA1 (0.63) | NR1H2NR1H3POLA1LMNACYP3A4 | |
| SCHEMBL21569919 | 0.84 | NR1H2 (0.62) | NR1H2NR1H3POLA1SOD1LMNA | |
| SCHEMBL24591989 | 0.84 | NR1H2 (0.62) | NR1H2NR1H3POLA1SOD1LMNA | |
| SCHEMBL2986350 | 0.81 | LMNA (0.65) | NR1H2NR1H3POLA1SOD1LMNA | |
| SCHEMBL20561119 | 0.81 | POLA1 (0.71) | NR1H2NR1H3POLA1LMNACYP3A4 | |
| SCHEMBL21552174 | 0.79 | NR1H2 (0.77) | NR1H2NR1H3POLA1SOD1 | |
| SCHEMBL29295121 | 0.78 | NR1H2 (0.56) | NR1H2NR1H3POLA1SOD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3790899-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.